Akero Therapeutics Inc diskutieren
Akero Therapeutics Inc
WKN: A2PLNP / Symbol: AKRO / Name: Akero Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
18,26 €
0,19 %
Buy Akero Therapeutics Inc
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $58.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $83.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Evercore ISI from $50.00 to $60.00. They now have an "outperform" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $69.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $69.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at Morgan Stanley from $70.00 to $33.00. They now have an "overweight" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at Cantor Fitzgerald from $69.00 to $39.00. They now have an "overweight" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at HC Wainwright from $64.00 to $40.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target lowered by analysts at UBS Group AG from $83.00 to $39.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $40.00 price target on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at HC Wainwright from $40.00 to $43.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at UBS Group AG from $39.00 to $42.00. They now have a "buy" rating on the stock.
Ratings data for AKRO provided by MarketBeat
Neueste Beiträge
StockNews_com in Hudson Global Inc. diskutieren